Ask AI
ProCE Banner Activity

HERIZON-GEA-01: PD-L1 Subgroup Analysis From Phase III Trial of Zanidatamab + Chemotherapy ± Tislelizumab for First-line HER2+ Locally Advanced or Metastatic GEA

Conference Coverage
Slideset

Results from the phase III HERIZON-GEA-01 trial showed clinically meaningful and statistically significant improvements in progression-free and overall survival with first-line zanidatamab plus chemotherapy and tislelizumab in patients with HER2-positive locally advanced or metastatic GEA, regardless of PD-L1 status.

Released: June 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Incyte Corporation.

Incyte Corporation

Lilly

PharmaMar

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of gastrointestinal cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from gastrointestinal cancer studies at ASCO 2026 and expert guidance to optimize patient selection, sequencing, and monitoring across major gastrointestinal malignancies

  • Utilize prognostic and predictive biomarkers to accurately identify gastrointestinal cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for gastrointestinal cancer to accelerate their effective incorporation into clinical practice